BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36960069)

  • 1. Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry.
    Ljungman P; Tridello G; Piñana JL; Ciceri F; Sengeloev H; Kulagin A; Mielke S; Yegin ZA; Collin M; Einardottir S; Lepretre SD; Maertens J; Campos A; Metafuni E; Pichler H; Folber F; Solano C; Nicholson E; Yüksel MK; Carlson K; Aguado B; Besley C; Byrne J; Heras I; Dignan F; Kröger N; Robin C; Khan A; Lenhoff S; Grassi A; Dobsinska V; Miranda N; Jimenez MJ; Yonal-Hindilerden I; Wilson K; Averbuch D; Cesaro S; Xhaard A; Knelange N; Styczynski J; Mikulska M; de la Camara R
    Front Immunol; 2023; 14():1125824. PubMed ID: 36960069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: a prospective multinational Infectious Disease Working Party from the European Society for Blood and Marrow Transplantation group (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH) study.
    Averbuch D; de la Camara R; Tridello G; Knelange NS; Bykova TA; Ifversen M; Dobsinska V; Ayas M; Hamidieh AA; Pichler H; Perez-Martinez A; Cesaro S; Sundin M; Badell I; Bader P; Johansson JE; Mirci-Danicar O; Sedlacek P; Paillard C; Gibson B; Lawson S; Kroeger N; Corbacioglu S; Mikulska M; Piñana JL; Styczynski J; Ljungman P
    Bone Marrow Transplant; 2023 May; 58(5):558-566. PubMed ID: 36849806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT.
    Schmidt-Hieber M; Tridello G; Ljungman P; Mikulska M; Knelange N; Blaise D; Socié G; Volin L; Blijlevens N; Fegueux N; Yakoub-Agha I; Forcade E; Maertens J; Chevallier P; Passweg J; Cornelissen J; Russell N; Craddock C; Bourhis JH; Marchand T; Reményi P; Cahn JY; Michallet M; Montoto S; Kröger N; Glaß B; Styczynski J
    Ann Hematol; 2019 Jul; 98(7):1755-1763. PubMed ID: 30993417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative Impact of Cytomegalovirus Reactivation on Survival in Adult Patients with Aplastic Anemia after an Allogeneic Hematopoietic Stem Cell Transplantation: A Report from Transplantation-Related Complication and Adult Aplastic Anemia Working Groups of the Japan Society for Hematopoietic Cell Transplantation.
    Takenaka K; Onishi Y; Mori T; Hirakawa T; Tada Y; Uchida N; Kobayashi T; Kanda Y; Ozawa Y; Ota S; Iida H; Fukushima K; Kimua T; Fukuda T; Atsuta Y; Matsuto K; Yamazaki H; Nakasone H
    Transplant Cell Ther; 2021 Jan; 27(1):82.e1-82.e8. PubMed ID: 33039517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis.
    Ljungman P; Brand R; Einsele H; Frassoni F; Niederwieser D; Cordonnier C
    Blood; 2003 Dec; 102(13):4255-60. PubMed ID: 12933590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey.
    Ljungman P; de la Camara R; Mikulska M; Tridello G; Aguado B; Zahrani MA; Apperley J; Berceanu A; Bofarull RM; Calbacho M; Ciceri F; Lopez-Corral L; Crippa C; Fox ML; Grassi A; Jimenez MJ; Demir SK; Kwon M; Llamas CV; Lorenzo JLL; Mielke S; Orchard K; Porras RP; Vallisa D; Xhaard A; Knelange NS; Cedillo A; Kröger N; Piñana JL; Styczynski J
    Leukemia; 2021 Oct; 35(10):2885-2894. PubMed ID: 34079042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Cytomegalovirus Reactivation by Recipient Cytomegalovirus-IgG Titer before Allogeneic Hematopoietic Stem Cell Transplantation.
    Kawamura S; Nakasone H; Takeshita J; Kimura SI; Nakamura Y; Kawamura M; Yoshino N; Misaki Y; Yoshimura K; Matsumi S; Gomyo A; Akahoshi Y; Kusuda M; Kameda K; Tanihara A; Tamaki M; Kako S; Kanda Y
    Transplant Cell Ther; 2021 Aug; 27(8):683.e1-683.e7. PubMed ID: 33984537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumocystis Pneumonia After Allogeneic Hematopoietic Cell Transplantation: A Case-Control Study on Epidemiology and Risk Factors on Behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation.
    Robin C; Cordonnier C; Tridello G; Knelange N; Xhaard A; Chantepie S; Tanguy-Schmidt A; Schouten HC; Yeshurun M; Rocha V; Srour M; Kröger N; Ledoux MP; Dalgaard J; Thiebaut A; Giardino S; Calore E; Zuckerman T; Groll AH; Raida L; Avcin S; Vicent MG; Kaare A; Drozd-Sokolowska J; Turlure P; Bretagne S; Mikulska M; Camara R; Cesaro S; Styczynski J
    Transplant Cell Ther; 2024 Feb; 30(2):235.e1-235.e10. PubMed ID: 38007092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT.
    Schmidt-Hieber M; Labopin M; Beelen D; Volin L; Ehninger G; Finke J; Socié G; Schwerdtfeger R; Kröger N; Ganser A; Niederwieser D; Polge E; Blau IW; Mohty M
    Blood; 2013 Nov; 122(19):3359-64. PubMed ID: 24037724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
    Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
    Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.
    Sharma A; Bhatt NS; St Martin A; Abid MB; Bloomquist J; Chemaly RF; Dandoy C; Gauthier J; Gowda L; Perales MA; Seropian S; Shaw BE; Tuschl EE; Zeidan AM; Riches ML; Shah GL
    Lancet Haematol; 2021 Mar; 8(3):e185-e193. PubMed ID: 33482113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry.
    Hernández-Boluda JC; Pereira A; Kröger N; Cornelissen JJ; Finke J; Beelen D; de Witte M; Wilson K; Platzbecker U; Sengeloev H; Blaise D; Einsele H; Sockel K; Krüger W; Lenhoff S; Salaroli A; Martin H; García-Gutiérrez V; Pavone V; Alvarez-Larrán A; Raya JM; Zinger N; Gras L; Hayden P; Czerw T; P McLornan D; Yakoub-Agha I
    Am J Hematol; 2021 Oct; 96(10):1186-1194. PubMed ID: 34152630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group.
    Kimura SI; Tamaki M; Okinaka K; Seo S; Uchida N; Igarashi A; Ozawa Y; Ikegame K; Eto T; Tanaka M; Shiratori S; Nakamae H; Sawa M; Kawakita T; Onizuka M; Fukuda T; Atsuta Y; Kanda Y; Nakasone H
    Ann Hematol; 2021 Dec; 100(12):3029-3038. PubMed ID: 34490500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
    Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
    Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation.
    Ljungman P; Brand R; Hoek J; de la Camara R; Cordonnier C; Einsele H; Styczynski J; Ward KN; Cesaro S;
    Clin Infect Dis; 2014 Aug; 59(4):473-81. PubMed ID: 24850801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus DNAemia detected with real-time polymerase chain reaction in hematopoietic stem cell transplant patients.
    Sahin DG; Gunduz E; Kasifoglu N; Akay OM; Us T; Gulbas Z
    Adv Ther; 2013 Aug; 30(8):784-91. PubMed ID: 23959787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
    Boeckh M; Bowden RA; Storer B; Chao NJ; Spielberger R; Tierney DK; Gallez-Hawkins G; Cunningham T; Blume KG; Levitt D; Zaia JA
    Biol Blood Marrow Transplant; 2001; 7(6):343-51. PubMed ID: 11464977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.